$235.55 Million in Sales Expected for CONMED Co. (NASDAQ:CNMD) This Quarter

Analysts expect CONMED Co. (NASDAQ:CNMDGet Rating) to report sales of $235.55 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for CONMED’s earnings, with the highest sales estimate coming in at $236.60 million and the lowest estimate coming in at $234.60 million. CONMED reported sales of $232.68 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 1.2%. The firm is expected to report its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that CONMED will report full year sales of $1.09 billion for the current fiscal year, with estimates ranging from $1.09 billion to $1.10 billion. For the next financial year, analysts expect that the company will post sales of $1.18 billion, with estimates ranging from $1.17 billion to $1.20 billion. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover CONMED.

Separately, StockNews.com began coverage on CONMED in a research report on Thursday, March 31st. They set a “hold” rating for the company.

Shares of NASDAQ CNMD opened at $140.86 on Friday. CONMED has a fifty-two week low of $117.62 and a fifty-two week high of $159.11. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 72.61, a price-to-earnings-growth ratio of 3.11 and a beta of 1.53. The company has a quick ratio of 1.16, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.

CONMED Company Profile (Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

Featured Stories

Get a free copy of the Zacks research report on CONMED (CNMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.